• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Oral Anticoagulants in Liver Disease: Not Child's Play.

作者信息

Hylek Elaine M, Anania Frank A

机构信息

Boston University School of Medicine, Boston, Massachusetts.

Division of Gastroenterology and Inborn Error Products, Center for Drug Evaluation and Research, Office of New Drugs/ODE III, U.S. Food and Drug Administration, Silver Spring, Maryland.

出版信息

J Am Coll Cardiol. 2019 Jul 2;73(25):3309-3311. doi: 10.1016/j.jacc.2019.05.009.

DOI:10.1016/j.jacc.2019.05.009
PMID:31248552
Abstract
摘要

相似文献

1
Oral Anticoagulants in Liver Disease: Not Child's Play.肝病中的口服抗凝剂：并非易事。
J Am Coll Cardiol. 2019 Jul 2;73(25):3309-3311. doi: 10.1016/j.jacc.2019.05.009.
2
Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.心房颤动卒中后抗凝治疗的三个月风险效益概况：SAMURAI-非瓣膜性心房颤动（NVAF）研究
Int J Stroke. 2016 Jul;11(5):565-74. doi: 10.1177/1747493016632239. Epub 2016 Feb 29.
3
Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials.非维生素 K 拮抗剂口服抗凝剂与华法林在 III 期心房颤动试验中的净临床获益。
Am J Med. 2015 Sep;128(9):1007-14.e2. doi: 10.1016/j.amjmed.2015.03.034. Epub 2015 Apr 22.
4
Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.低剂量非维生素K拮抗剂口服抗凝药与华法林在房颤患者中的有效性和安全性：倾向评分加权的全国队列研究
BMJ. 2017 Feb 10;356:j510. doi: 10.1136/bmj.j510.
5
Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: the SAMURAI-NVAF study.日本非瓣膜性心房颤动急性卒中患者口服抗凝剂选择的趋势：SAMURAI-NVAF研究
Int J Stroke. 2015 Aug;10(6):836-42. doi: 10.1111/ijs.12452. Epub 2015 Jan 12.
6
Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation.左心耳封堵术与华法林或非维生素 K 拮抗剂口服抗凝剂用于非瓣膜性心房颤动二级预防的成本效益比较：WATCHMAN 装置。
Stroke. 2018 Jun;49(6):1464-1470. doi: 10.1161/STROKEAHA.117.018825. Epub 2018 May 8.
7
Stroke prevention in the elderly atrial fibrillation patient with comorbid conditions: focus on non-vitamin K antagonist oral anticoagulants.老年合并症心房颤动患者的卒中预防：聚焦于非维生素K拮抗剂口服抗凝药。
Clin Interv Aging. 2015 Sep 3;10:1431-44. doi: 10.2147/CIA.S80641. eCollection 2015.
8
Use of oral anticoagulants in complex clinical situations with atrial fibrillation.在伴有房颤的复杂临床情况下使用口服抗凝药物。
Med Clin (Barc). 2018 Jun;150 Suppl 1:8-24. doi: 10.1016/S0025-7753(18)30666-3.
9
Persistence and outcomes of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation.非维生素K拮抗剂类口服抗凝药与华法林在非瓣膜性心房颤动患者中的疗效持久性及转归
J Clin Nurs. 2019 May;28(9-10):1839-1846. doi: 10.1111/jocn.14797. Epub 2019 Feb 12.
10
Non-Vitamin K Antagonist Oral Anticoagulants in the Treatment of Atrial Fibrillation.非维生素 K 拮抗剂口服抗凝药在心房颤动治疗中的应用。
Annu Rev Med. 2019 Jan 27;70:61-75. doi: 10.1146/annurev-med-042617-092334. Epub 2018 Nov 26.

引用本文的文献

1
Efficacy and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and liver disease: an updated systematic review and meta-analysis.直接口服抗凝剂与华法林在房颤合并肝病患者中的疗效和安全性：一项更新的系统评价和荟萃分析
Arch Med Sci Atheroscler Dis. 2025 May 30;10:e78-e88. doi: 10.5114/amsad/205549. eCollection 2025.
2
Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review.直接口服抗凝剂在非酒精性脂肪性肝病全球流行时代肝病患者中的应用：一项叙述性综述。
Adv Ther. 2020 May;37(5):1910-1932. doi: 10.1007/s12325-020-01307-z. Epub 2020 Apr 13.